Skip to main content
. 2016 May 31;76(1):208–213. doi: 10.1136/annrheumdis-2015-208849

Figure 1.

Figure 1

(A) Certolizumab concentration–effect curve at 6 months (using drug-level thresholds). (B) Certolizumab concentration–effect curve at 6 months (deciles). (C) Certolizumab levels in European League Against Rheumatism (EULAR) good, moderate and non-responders at 12 months.